Lupus Nephritis Treatment Developer's Board Chair Acquires Approximately 17 Billion Won in Shares

Kevin Tang, Chairman of the Board of U.S. biotech company Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), indirectly purchased approximately 900,000 shares of the company’s common stock in open-market transactions on February 27 and March 2–3. The shares were acquired at prices ranging from about $13.90 to $14.33 each, for a total of roughly $12.7 million (approximately KRW 17 billion), bringing Tang’s indirect holding to around 12.2 million shares.

On February 26, Aurinia reported its financial results for the fourth quarter and full year ended December 31, 2025, noting that sales of its lupus nephritis treatment LUPKYNIS grew by about 25% year over year. The company also issued guidance for 2026 total revenues of $315 million to $325 million. ()

Aurinia is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases such as lupus nephritis. LUPKYNIS is the first oral therapy approved by the U.S. Food and Drug Administration for adult patients with active lupus nephritis. ()

Kevin Tang is the founder and CEO of life-science–focused investment firm Tang Capital Management and has served as Aurinia’s board chair since 2024. ()